BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05399368 (RPT193 in Atopic Dermatitis): BVCT ex-ante prediction vs. reported outcome

On 10 Aug 2023, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 9 May 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05399368
Drug Name
RPT193
Drug MoA
oral CCR4 inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Skin and Connective Tissue Diseases
Indication
Atopic Dermatitis
Human Patients
229
Sponsor
RAPT Therapeutics
Phase
Phase 2

Prediction of , index 1212

Prospective Prediction
Prediction Index
1212
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
FAILURE (statistically insignificant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
273 days in advance
Readout Data Interpretation
terminated due to clinical holds.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 as Monotherapy in Adults With Moderate-to-Severe Atopic Dermatitis
Phase
Phase 2
Status
Terminated
Enrollment
229
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Conditions
Atopic Dermatitis
Interventions
DRUG: RPT193; OTHER: Placebo
Design
Randomized · Parallel · Triple
Primary purpose
Treatment
Start
2022-06-07
Primary completion
2024-05-24
Completion
2024-05-24
Results first posted
2026-02-25
Primary outcomes
  • To Evaluate the Clinical Efficacy of RPT193 Administered Orally Once Daily (QD) for 16 Weeks to Participants With Moderate-to-severe AD (16 weeks)

NCT05399368 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials